ATRA Stock Recent News
ATRA LATEST HEADLINES
LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.
LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES, CA / ACCESS Newswire / January 31, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.